Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0003315,
umls-concept:C0025202,
umls-concept:C0026473,
umls-concept:C0030705,
umls-concept:C0039195,
umls-concept:C0205251,
umls-concept:C0205263,
umls-concept:C0205369,
umls-concept:C0376249,
umls-concept:C0385723,
umls-concept:C0439185,
umls-concept:C0870134,
umls-concept:C0879593,
umls-concept:C1332710,
umls-concept:C1334510,
umls-concept:C1441547,
umls-concept:C1518997,
umls-concept:C1709634
|
| pubmed:issue |
24
|
| pubmed:dateCreated |
1998-1-8
|
| pubmed:abstractText |
Peptide presentation by autologous dendritic cells (DCs) is a new tool to activate tumor antigen-specific T cells in melanoma patients. However, it is not known whether autologous DCs, differentiated by two of the most efficient protocols (from CD34+ progenitors or from monocytes), are equally effective as professional antigen-presenting cells (APCs) when the patients have a low frequency of peptide-specific precursors. To this end, a limiting dilution assay was applied to evaluate the frequency of antigen-specific CTL precursors (CTLps) in peripheral blood of HLA-A*0201+ melanoma patients. Then, from two melanoma patients showing low frequency of CTLps to melanoma antigen-A/melanoma antigen recognized by T cell (Melan-A/Mart-1)(27-35) peptide, autologous DCs were differentiated from granulocyte colony-stimulating factor-mobilized CD34+ progenitors or from monocytes. CD34+- and monocyte-derived DCs were characterized by a similar proportion of CD1a+ cells expressing HLA class II antigens and CD54, CD80, and CD86 molecules. Both types of DC presented Melan-A/Mart-1(27-35) and tyrosinase(369-377) peptides to melanoma-specific CTL clones and were equally effective as peptide-pulsed APCs in the activation of influenza A matrix(58-66)-specific CTLs from high-frequency precursors (1294/10(6) and 1789/10(6) lymphocytes in the two patients). However, efficient activation of Melan-A/Mart-1(27-35)-specific CTLs from low-frequency precursors (158/10(6) and 77/10(6) lymphocytes) of the two patients was markedly dependent on the use of peptide-loaded CD34+-derived DCs. These results suggest that CD34+- and monocyte-derived DCs are not functionally equivalent APCs for the activation of low-frequency peptide-specific CTLps.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Dec
|
| pubmed:issn |
0008-5472
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
57
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
5534-41
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9407964-Antigen-Presenting Cells,
pubmed-meshheading:9407964-Antigens, CD34,
pubmed-meshheading:9407964-Dendritic Cells,
pubmed-meshheading:9407964-Hematopoietic Stem Cells,
pubmed-meshheading:9407964-Humans,
pubmed-meshheading:9407964-Lymphocyte Activation,
pubmed-meshheading:9407964-Melanoma,
pubmed-meshheading:9407964-Monocytes,
pubmed-meshheading:9407964-Phenotype,
pubmed-meshheading:9407964-T-Lymphocytes, Cytotoxic
|
| pubmed:year |
1997
|
| pubmed:articleTitle |
Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors.
|
| pubmed:affiliation |
Division of Experimental Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. mortarini@istituotumori.mi.it
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|